Wildcat Capital, which manages funds for the American billionaire David Bonderman, has called for management changes at a pharmaceutical firm, representing a rare public case of shareholder activism by a family office.
In a strongly worded letter, Wildcat raised concerns over corporate governance at Sorrento Therapeutics and said the chief executive, Henry Ji, should be replaced.
